Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Roxicodone(R) Tablets
Date:5/14/2009

DETROIT, May 14 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has recently launched oxycodone hydrochloride tablets on behalf of Sun Pharmaceutical Industries Inc., a subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma), following Sun Pharma's recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Roxicodone(R) tablets.

Oxycodone hydrochloride tablets are an immediate-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. These generic versions of oxycodone 5 mg, 15 mg, and 30 mg tablets are therapeutically equivalent to Roxicodone(R) tablets from Xanodyne Pharmaceuticals Inc. According to IMS Data, these strengths of oxycodone tablets had US sales of approximately $160 million for the calendar year of 2008.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to add this product to our portfolio and help address the current shortage in the marketplace by launching oxycodone tablets. We continue to focus on working towards expanding our product offerings both as a marketing partner and through our own development pipeline of products as quickly and effectively as possible."

Roxicodone(R) is a registered trademark of Xanodyne Pharmaceuticals Inc.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisi
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Empire BlueCross BlueShield Appoints Chief Medical Officer 2Health News:'Positively Conscious: An Enlightened Look At Life' 2Health News:PatentStorm Releases U.S. Patent Applications and Other Features 2Health News:Former Mayor of Indianapolis to Serve as a Senior Strategic Advisor to McKenna Long & Aldridge LLP's Global Infrastructure Finance and Public-Private Partnerships Practice 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 3Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 4Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 5Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 2Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 3Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 4
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 2Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 3Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 4Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 5Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 6Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 7Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 8Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 2Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 3Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 4Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 5Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 8Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 10Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 11Nearly 9 in 10 Seniors Satisfied With Medigap 48743 1Nearly 9 in 10 Seniors Satisfied With Medigap 48743 2Nearly 9 in 10 Seniors Satisfied With Medigap 48743 3A Robot That Reads Your Mind 3F 48740 1A Robot That Reads Your Mind 3F 48740 2The Stress of Sudden Fame Made Anxiety Attacks Headline News 48736 1The Stress of Sudden Fame Made Anxiety Attacks Headline News 48736 2
Other Medicine Technology:New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 2New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 3New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 4New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 5New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 6New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 7U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 2U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 3U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 4U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 5